Livent has more to lose if this merger does not proceed.
imo Allkem should have a greater ratio of the new merged company. The shorts could be twofold, one Livent reports a poor result, shorts will pile in further and two the merger “may” fail, shorts get their pay day.
- Forums
- ASX - By Stock
- AKE
- Ann: September quarterly activities report
Ann: September quarterly activities report, page-64
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AKE (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online